The Effects of Statin and Fibrate on Lowering Small Dense LDL- Cholesterol in Hyperlipidemic Patients with Type 2 Diabetes

Tokuno, Anna; Hirano, Tsutomu; Hayashi, Toshiyuki; Mori, Yusaku; Yamamoto, Takakazu; Nagashima, Masaharu; Shiraishi, Yuji; Ito, Yasuki; Adachi, Mitsuru

doi:10.5551/jat.14.128

Cited by 56 publications

(50 citation statements)

References 18 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LDL-C, low-density lipoprotein cholesterol; Apo, apolipoprotein; sd-LDL-C, small dense low-density lipoprotein cholesterol; lb-LDL-C, large buoyant low-density lipoprotein cholesterol; RLP-C, remnant-like particle cholesterol. sd-LDL-C levels determined by this method were 37 20 mg/dL in hypercholesterolemic subjects with type 2 diabetes and 45 21 mg/dL in hypertriglyceridemic subjects with type 2 diabetes 31) . Compared with these data, mean levels of sd-LDL-C (44 20 mg/dL) in heterozygous FH were equal to or more than in subjects with MetS or type 2 diabetes.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, percent changes of sd-LDL-C levels were higher than percent changes of lb-LDL-C levels in both statins. Sd-LDL particles have weaker affinity to LDL receptors than lb-LDL particles 40) ; however, a recent study indicated that the induction of LDL receptors by statin stimulated the uptake of all LDL particles, irrespective of their size 31) . According to this report, a low dose of pitavastatin (1 mg) decreased sd-LDL-C levels by 26% and lb-LDL-C levels by 22%.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Statin on Small Dense Low-Density Lipoprotein Cholesterol and Remnant-Like Particle Cholesterol in Heterozygous Familial Hypercholesterolemia

Nozue

Michishita

Ito

et al. 2008

JAT

Self Cite

View full text Add to dashboard Cite

Aim:The effects of statin on small dense low-density lipoprotein cholesterol (sd-LDL-C) and remnant-like particle cholesterol (RLP-C) levels in heterozygous familial hypercholesterolemia (FH) have not been examined. This study aimed to clarify the effects of statin on sd-LDL-C and RLP-C levels in heterozygous FH. Methods: Seventeen patients with heterozygous FH were randomly assigned to 2 mg/day pitavastatin or 10 mg/day atorvastatin. At baseline and 12 weeks after treatment with statin, we measured sd-LDL-C and RLP-C levels.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Effects of Statin on Small Dense Low-Density Lipoprotein Cholesterol and Remnant-Like Particle Cholesterol in Heterozygous Familial Hypercholesterolemia

Nozue

Michishita

Ito

et al. 2008

JAT

Self Cite

View full text Add to dashboard Cite

show abstract

“…It has been reported that the sd-LDL-lowering effects of statin treatment may be due to the reduction of total-LDL levels rather than their effects on LDL size 22,23) . Tokuno et al 24) observed that 3 months of pitavastatin treatment in type-2 diabetes reduced sd-LDL by 26% and LDL by 25%, while micronized phenofibrate reduced sd-LDL by 23% without any effect on LDL.…”

Section: Discussionmentioning

confidence: 99%

Effects of Different Statin Treatments on Small Dense Low-Density Lipoprotein in Patients with Metabolic Syndrome

Bahadir¹,

Oğuz

Uzunlulu³

et al. 2009

JAT

View full text Add to dashboard Cite

Aim: To compare the effects of different low-density lipoprotein (LDL) cholesterol-lowering statin treatments on small dense LDL (sd-LDL) in hypercholesterolemic patients with metabolic syndrome (MetS). Methods: Forty hypercholesterolemic MetS patients ≥ 30 years of age were randomized to rosuvastatin (n 17) or other statins (n 23) groups. In the other statins group, those taking atorvastatin (n 12) were also evaluated separately. Statin doses were 10 mg/day rosuvastatin, 20 mg/day atorvastatin, 40 mg/day simvastatin, and 40 mg/day pravastatin. Treatment duration was planned to be 8 weeks. Sd-LDL levels were assessed at baseline and at the completion of treatment. Results: After treatment, sd-LDL levels were significantly reduced in all 3 groups (from 29.6 24.8 mg/dL to 8.9 8.5 mg/dL in the rosuvastatin group, p 0.001; from 26.2 15 mg/dL to 14.8 9.6 mg/dL in the atorvastatin group, p 0.02; and from 29.1 16.5 mg/dL to 14.7 11.2 mg/dL in the other statins group, p 0.0001). There was no significant difference in the mean percent changes among groups. Conclusion: Significant reduction in sd-LDL levels was observed after 8 weeks of statin treatment in hypercholesterolemic patients with MetS. This effect was similar for all statins and can be considered a class effect. J Atheroscler

show abstract

“…Fenofibrate, one of the fibrate classes of hypolipidemic drugs, is known as an agonist for PPAR ; it lowers plasma levels of triglyceride and LDL-cholesterol, and raises plasma HDL-cholesterol concentrations [10][11][12] . Previous studies have demonstrated the respective effects of EPA and DHA on metabolic control.…”

Section: Introductionmentioning

confidence: 99%

Anti-Obesity Effect of Fish Oil and Fish Oil-Fenofibrate Combination in Female KK Mice

Arai

Kim

Chiba

et al. 2009

JAT

View full text Add to dashboard Cite

Aim:The aim of our study is to elucidate the effects of EPA-or DHA-rich fish oil, and of the latter plus fenofibrate, on lipid metabolism in female KK mice. Methods: Female KK mice were fed purified experimental diets containing lard/safflower oil (4:6, Lard/SO), EPA-rich fish oil (EPA), DHA-rich fish oil (DHA), or DHA-rich fish oil plus 0.2% (w/w) fenofibrate (DHA FF) for 8 weeks. At the end of the experiments, we measured levels of plasma lipids, hepatic triglycerides, and cholesterol, as well as the hepatic mRNA expression of lipogenic and lipidolytic genes. Results: The final body weight of EPA-and DHA-fed groups was significantly lower than that of the Lard/SO-fed group, and that of the DHA FF-fed group was the lowest. All three fish oil treatments significantly reduced plasma insulin levels. Hepatic lipid levels significantly decreased in all three of these groups compared with the Lard/SO-fed group. Plasma adiponectin increased in both the EPAand DHA-fed groups, but the increase was suppressed in the DHA FF-fed group. Hepatocytes of Lard/SO-fed mice were filled with numerous fat droplets, but fat accumulation was inhibited in both EPA-and DHA-fed mice and was significantly prevented by fenofibrate treatment. SREBP-1c mRNA levels were decreased by about half in EPA-and DHA-fed mice compared with Lard/SO-fed mice. FAS, Insig-1, HMG-CoA reductase, and LDL-receptor mRNA levels also markedly decreased in both EPA-and DHA-fed mice, but there was no additional decrease in DHA FF fed mice. Fenofibrate treatment significantly induced mRNA expression of AOX and UCP-2, but not of PPAR . Conclusion: These data suggest that fish oil inhibited body weight gain and exhibited an anti-obesity effect through the inhibition of lipid synthesis in female KK mice. Furthermore, fenofibrate treatment markedly inhibited body weight gain by the induction of fatty acid oxidation. Plasma adiponectin levels did not increase in mice fed DHA-rich fish oil with fenofibrate, although white adipose tissue (WAT) weight significantly decreased. We considered that adiponectin sensitivity increased more in mice fed DHA-rich fish oil with fenofibrate than in mice fed DHA-rich fish oil alone.

show abstract

The Effects of Statin and Fibrate on Lowering Small Dense LDL- Cholesterol in Hyperlipidemic Patients with Type 2 Diabetes

Cited by 56 publications

References 18 publications

Effects of Statin on Small Dense Low-Density Lipoprotein Cholesterol and Remnant-Like Particle Cholesterol in Heterozygous Familial Hypercholesterolemia

Effects of Statin on Small Dense Low-Density Lipoprotein Cholesterol and Remnant-Like Particle Cholesterol in Heterozygous Familial Hypercholesterolemia

Effects of Different Statin Treatments on Small Dense Low-Density Lipoprotein in Patients with Metabolic Syndrome

Anti-Obesity Effect of Fish Oil and Fish Oil-Fenofibrate Combination in Female KK Mice

Contact Info

Product

Resources

About